

RNAi

Technologies, Companies and Markets

By

Prof. K. K. Jain
MD, FRACS, FFPM
Jain PharmaBiotech
Basel, Switzerland

June 2018

A Jain PharmaBiotech Report

A U T H O R ' S B I O G R A P H Y

Professor K. K. Jain is a neurologist/neurosurgeon by training and has been working in the biotechnology/biopharmaceuticals industry for several years. He received graduate training in both Europe and US, has held academic positions in several countries and is a Fellow of the Faculty of Pharmaceutical Medicine of the Royal College of Physicians of UK. Currently he is a consultant at Jain PharmaBiotech. Prof. Jain's 476 publications include 30 books (6 as editor + 24 as author) and 50 special reports, which have covered important areas in biotechnology, gene therapy and biopharmaceuticals.

In 1998, Prof. Jain wrote a Textbook of Gene Therapy, which was the first book on this subject to be translated into the Chinese language in 2000. A book on gene therapy companies was published in 2000 by John Wiley & Sons and continued to be updated online at Wiley's web site until 2003 and is currently incorporated in the report on gene therapy published by Jain PharmaBiotech and is regularly updated with latest edition in 2015. Prof. Jain has edited "Drug Delivery Systems" (1st ed Humana/Springer 2008, 2nd ed 2014) and Drug Delivery to the Central Nervous System (Humana/Springer 2010). His other recent books include "Handbook of Nanomedicine" (Humana/Springer 2008; Chinese edition, Peking University Press 2011, 2nd ed Springer 2012, 3rd ed 2017), "Textbook of Personalized Medicine" (Springer 2009; Japanese ed 2012; 2nd ed Springer, 2015), "Handbook of Biomarkers" (Springer 2010; Chinese edition, Chemical Industry Press 2016, 2nd ed Springer 2017), "Handbook of Neuroprotection" (Springer 2011, 2nd edn 2018, in preparation), "Application of Biotechnology in Cardiovascular Therapeutics" (Springer 2011), "Application of Biotechnology in Neurology" (Springer 2013), and "Applications of Biotechnology in Oncology" (Springer, 2014). He has edited "Applied Neurogenomics" (Springer 2015).

June 2018
Copyright © 2018 by

Jain PharmaBiotech
Bläsiring 7
CH-4057 Basel
Switzerland

Tel & Fax: **+4161-6924461**
Email: **info@pharmabiotech.ch**
Web site: **http://pharmabiotech.ch/**

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, or otherwise without the prior written permission of the Publisher. This report may not be lent, resold or otherwise traded in any manner without the consent of the Publisher. While all reasonable steps have been taken to ensure the accuracy of the information presented, the Publisher cannot accept responsibility for inadvertent errors or omissions.

TABLE OF CONTENTS

0. Executive Summary	16
1. Technologies for suppressing gene function	18
Introduction	18
DNA transcription.....	18
RNA	18
<i>Non-coding RNA</i>	<i>18</i>
<i>RNA research and potential applications.....</i>	<i>20</i>
<i>Role of RNA in regulation of the dihydrofolate reductase gene</i>	<i>22</i>
Gene regulation	22
Post-transcriptional regulation of gene expression.....	23
Alternative RNA splicing.....	24
Technologies for gene suppression	24
Antisense oligonucleotides	24
Phosphorodiamidate morpholino oligomers.....	25
Transcription factor decoys	25
Aptamers.....	26
Ribozymes	26
Aptazymes.....	27
RNA aptamers vs allosteric ribozymes	27
Peptide nucleic acid.....	27
PNA-DNA chimeras.....	28
Locked nucleic acid	28
Long noncoding RNAs.....	28
Gene silencing	29
Post-transcriptional gene silencing	29
Small noncoding RNAs.....	30
TargetTron™ technology for gene knockout.....	31
Definitions and terminology of RNAi	31
RNAi mechanisms	32
RNAi oligonucleotides	34
Non-promoter-associated small RNAs.....	34
Piwi-interacting RNAs in germ cell development	35
Relation of RNAi to junk DNA.....	35
RNAi and epigenetic mechanisms	36
RNA editing and RNAi	36
Historical landmarks in the development of RNAi	36
2. RNAi Technologies	38
Introduction	38
Comparison of antisense and RNAi	38
Advantages of antisense over siRNAs	38
Advantages of siRNAs over antisense	39
RNA aptamers vs siRNA	39
RNA Lassos versus siRNA.....	39
Concluding remarks on antisense vs RNAi	40
PMOs vs antisense and siRNAs	40
ssRNAi	40
Antisense vs DNP-ssRNA and DNP-siRNA	40
LNA and RNAi.....	41
LNA for gene suppression.....	41
Comparison of LNA and RNAi.....	42
Use of siLNA to improve siRNA.....	42
RNAi versus small molecules	42
RNAi in vivo	43
Cre-regulated RNAi in vivo	43
RNAi kits.....	43
ShortCut™ RNAi Kit.....	43
HiScribe™ RNAi Transcription Kit	44
pSUPER RNAi system.....	44
Si2 Silencing Duplex.....	45
Techniques for measuring RNAi-induced gene silencing	45
Application of PCR in RNAi.....	45
<i>Real-time quantitative PCR.....</i>	<i>46</i>
<i>Assessment of the silencing effect of siRNA by RT-PCR</i>	<i>46</i>
<i>Fluorescence resonance energy transfer probe for RNA interactions</i>	<i>47</i>
Bioinformatics tools for design of siRNAs	47

Random siRNA design.....	47
Rational siRNA design.....	48
<i>The concept of pooling siRNAs</i>	49
<i>Criteria for rational siRNA design</i>	49
<i>BLOCK-iT RNAi Designer</i>	49
<i>QIAGEN's 2-for-Silencing siRNA Duplexes</i>	50
<i>Designing vector-based siRNA</i>	50
<i>iRNAChek for designing siRNA</i>	50
<i>TROD: T7 RNAi Oligo Designer</i>	50
<i>siDirect: siRNA design software</i>	51
Prediction of efficacy of siRNAs.....	51
<i>Algorithms for prediction of siRNA efficacy</i>	51
<i>siRNA databases</i>	51
Production of siRNAs	52
Chemical synthesis of short oligonucleotides.....	52
In vitro transcription.....	52
Generation of siRNAs in vivo.....	53
UsiRNAs.....	53
siRNA:DNA hybrid molecules.....	54
Chemical modifications of siRNAs.....	54
<i>Sugar modifications of siRNA</i>	54
<i>Phosphate linkage modifications of siRNA</i>	54
<i>Modifications to the siRNA overhangs</i>	55
<i>Modifications to the duplex architecture</i>	55
<i>Applications of chemical modification of siRNAs</i>	55
Synthetic RNAs vs siRNAs.....	56
Specificity of siRNAs	56
Asymmetric interfering RNA	57
Genome-wide data sets for the production of esiRNAs	57
ddRNAi for inducing RNAi	57
ddRNAi technology.....	57
Advantages of ddRNAi over siRNA.....	58
Short hairpin RNAs	59
siRNA versus shRNA.....	59
Circular interfering RNA.....	60
Expressed interfering RNA	61
RNA-induced transcriptional silencing complex	61
Inhibition of gene expression by antigene RNA	62
RNAi vs mRNA modulation by small molecular weight compounds	62
saRNA for transcriptional activation	63
3. MicroRNA	64
Introduction	64
Circular RNA and miRNA	66
miRNA and RISC	66
Role of the microprocessor complex in miRNA	67
miRNAs compared to siRNAs	68
miRNA and stem cells	68
Influence of miRNA on stem cell formation and maintenance.....	68
Role of miRNAs in gene regulation during stem cell differentiation.....	69
miRNA databases	70
Sanger miRBase miRNA sequence database.....	70
Mapping miRNA genes.....	70
A database of ultraconserved sequences and miRNA function.....	71
A database for miRNA deregulation in human disease.....	71
An database of miRNA-target interactions.....	71
Role of miRNA in gene regulation	72
Control of gene expression by miRNA.....	72
<i>miRNA-mediated translational repression involving Piwi</i>	73
<i>Transcriptional regulators of ESCs control of miRNA gene expression</i>	73
Mechanism of miRNAs-induced silencing of gene expression.....	73
miRNA diagnostics	74
Biochemical approach to identification of miRNA.....	74
Computational approaches for the identification of miRNAs.....	74
LNA probes for exploring miRNA.....	74
miR-TRAP to identify miRNA targets in vivo.....	75
Microarrays for analysis of miRNA gene expression.....	75
<i>Microarrays vs quantitative PCR for measuring miRNAs</i>	76
miRNAs as biomarkers of hepatotoxicity.....	76
Modification of in situ hybridization for detection of miRNAs.....	77
Nuclease Protection Assay to measure miRNA expression.....	77

Real-time PCR for expression profiling of miRNAs.....	77
Significance of miRNAs in diagnostics	78
Targeting of miRNAs with antisense oligonucleotides	78
Silencing miRNAs by antagomirs.....	78
New tools for miRNA silencing	79
Use of HAPIScreen for identification of aptamers against pre-miRNAs	79
miRNA-regulated lentiviral vectors.....	79
miRNAs as drug targets	79
miRNAs as targets for antisense drugs.....	80
Challenges facing use of miRNAs as drug targets	80
Target specificity of miRNAs	81
Prediction of miRNA targets.....	81
Role of miRNA in human health and disease.....	82
Role of miRNAs in regulation of hematopoiesis.....	82
Role of miRNA depletion in tissue regeneration	83
Role of miRNA in regulation of aging	83
Role of miRNA in inflammation	83
Role of miRNAs in regulation of immune system	84
Role of miRNA in diabetes.....	84
Role of miRNA in the cardiovascular system	84
Role of miRNAs in development of the cardiovascular system	85
Role of miRNAs in angiogenesis	85
Role of miRNA in atherosclerosis.....	85
Role of miRNAs in cardiac hypertrophy and failure	85
Role of miRNA in cardiomyopathy	86
Role of miRNAs in conduction and rhythm disorders of the heart.....	87
Diagnostic and prognostic value of miRNAs in acute coronary syndrome	87
miRNA-based approaches for reduction of hypercholesterolemia	87
miRNA-based approach for restenosis following angioplasty	88
miRNA gene therapy for ischemic heart disease.....	88
miRNAs as therapeutic targets for cardiovascular diseases	89
Concluding remarks and future prospects of miRNA in the cardiovascular system.....	89
Role of miRNAs in diseases of the eye	89
Pathological ocular neovascularization	89
Role of miRNAs in diabetic retinopathy	90
Role of miRNAs in glaucoma.....	90
Role of miRNA in corneal scarring	90
Role of miRNAs in the nervous system.....	91
miRNAs and addiction.....	91
miRNAs in neurodegenerative disorders.....	92
<i>miRNAs as biomarkers of Alzheimer's disease.....</i>	<i>93</i>
<i>miRNAs in Parkinson disease</i>	<i>94</i>
<i>miRNAs in Huntington's disease.....</i>	<i>94</i>
<i>miRNAs in ALS.....</i>	<i>95</i>
<i>miRNAs as biomarkers of prion-induced neurodegeneration.....</i>	<i>96</i>
<i>miRNAs and retinal neurodegenerative disorders</i>	<i>96</i>
<i>miRNA and stroke</i>	<i>96</i>
<i>miRNA and schizophrenia.....</i>	<i>97</i>
Role of miRNA in neuroprotection.....	97
Role of miRNA in viral infections.....	98
Role of miRNA in HSV-1 latency.....	98
miRNA and autoimmune disorders.....	98
miRNA in rheumatoid arthritis	98
miRNA in systemic lupus erythematosus	99
miRNAs in gastrointestinal disorders.....	99
miRNA-based therapies for the irritable bowel syndrome	99
miRNA-based therapies for the inflammatory bowel disease	99
miRNA and skin disorders.....	100
Role of miRNA in inflammatory skin disorders.....	100
Role of miRNA in hypertrophic scarring of the skin	100
Role of miRNAs in cancer	100
miRNAs linked to the initiation and progression of cancer.....	101
Oncomirs	101
Linking miRNA sequences to cancer using RNA samples.....	102
Role of miRNAs in viral oncogenesis	102
miRNA genes in cancer	102
miRNAs interaction with p53	103
miRNAs, embryonic stem cells and cancer.....	104
miRNAs and cancer metastases	104
Role of miRNAs in cancer diagnosis	105
<i>Cancer miRNA signature</i>	<i>105</i>

<i>miRNA biomarkers in cancer</i>	105
<i>Diagnostic value of miRNA in cancer</i>	106
<i>Prognostic value of miRNA in cancer</i>	106
miRNA-based cancer therapeutics.....	106
<i>Antisense oligonucleotides targeted to miRNA</i>	107
<i>Role of miRNAs in adoptive immunotherapy of cancer</i>	107
<i>Restoration of tumor suppressor miRNAs to inhibit cancer</i>	107
<i>Delivery strategies for miRNA modulators in cancer</i>	108
Role of miRNAs in various cancers.....	109
<i>miRNA and brain tumors</i>	109
<i>miRNAs and CNS tumors in children</i>	111
<i>miRNAs and pituitary tumors</i>	112
<i>miRNA and breast cancer</i>	112
<i>miRNA and colorectal cancer</i>	113
<i>miRNA and gastrointestinal cancer</i>	113
<i>miRNA and leukemia</i>	114
<i>miRNA and lymphomas</i>	115
<i>miRNA and hepatocellular carcinoma</i>	115
<i>miRNA and lung cancer</i>	116
<i>miRNA and nasopharyngeal carcinoma</i>	117
<i>miRNA and ovarian cancer</i>	118
<i>miRNA and pancreatic cancer</i>	119
<i>miRNA and prostatic cancer</i>	119
<i>miRNA and thyroid cancer</i>	120
Companies involved in miRNA	120
Status of therapeutic development of miRNAs	121
Concluding remarks and future of miRNA therapeutics	122
4. Methods of delivery in RNAi	124
Introduction	124
Methods of delivery of oligonucleotides	124
Oral and rectal administration.....	125
Pulmonary administration.....	125
Targeted delivery to the CNS.....	126
<i>High flow microinfusion into the brain parenchyma</i>	126
Intracellular guidance by special techniques.....	126
Biochemical microinjection.....	127
Liposomes-mediated oligonucleotide delivery.....	127
Polyethylenimine-mediated oligonucleotide delivery.....	127
Delivery of TF Decoys.....	127
Biodegradable microparticles.....	128
<i>Microparticles</i>	128
<i>Nanoparticles</i>	128
Self-delivering rxRNA	129
siRNA delivery technologies	129
Local delivery of siRNA.....	130
In vivo delivery of siRNAs by synthetic vectors.....	130
Intracellular delivery of siRNAs.....	130
<i>Delivery of siRNAs with aptamer-siRNA chimeras</i>	131
<i>MPG-based delivery of siRNA</i>	132
<i>Protamine-antibody fusion proteins for delivery of siRNA to cells</i>	132
<i>Protein transduction domains</i>	132
<i>Phosphorothioate stimulated cellular delivery of siRNA</i>	133
Targeted delivery of siRNAs by lipid-based technologies.....	133
<i>Delivery of siRNA-lipoplexes</i>	133
<i>Lipidoids for delivery of siRNAs</i>	134
<i>NeoLipid™ technology</i>	134
<i>siFECTamine™</i>	134
<i>Systemic in vivo delivery of lipophilic siRNAs</i>	135
<i>Challenges and future prospects of lipid-based siRNA delivery</i>	135
Electroporation.....	135
<i>Nucleofactor technology</i>	136
<i>Visualization of electrotransfer of siRNA at single cell level</i>	136
Intravascular delivery of siRNA.....	136
27mer siRNA duplexes for improved delivery and potency.....	137
TransIT-TKO®.....	137
DNA-based plasmids for delivery of siRNA.....	138
<i>Convergent transcription</i>	139
PCR cassettes expressing siRNAs.....	139
Genetically engineered bacteria for delivery of shRNA.....	139
Viral vectors for delivery of siRNA.....	139

<i>Adenoviral vectors</i>	140
<i>Adeno-associated virus vectors for shRNA expression</i>	140
<i>Baculovirus vector</i>	140
<i>Lentiviral vectors</i>	141
<i>Retroviral delivery of siRNA</i>	142
Transkingdom RNAi delivery by genetically engineered bacteria	142
Delivery of siRNA without a vector	142
Cell-penetrating peptides for delivery of siRNAs	143
Role of nanobiotechnology in siRNA delivery	143
<i>Chitosan-coated nanoparticles for siRNA delivery</i>	143
<i>Cyclodextrin nanoparticles</i>	144
<i>Delivery of gold nanorod-siRNA nanoplex to dopaminergic neurons</i>	144
<i>Lipidic aminoglycoside as siRNA nanocarrier</i>	144
<i>Lipid nanoparticles-mediated siRNA delivery</i>	144
<i>Nanoparticles for intracellular delivery of siRNA</i>	145
<i>Nanosize liposomes for delivery of siRNA</i>	145
<i>PAMAM dendrimers for siRNA delivery</i>	146
<i>PEG-PCL-DEX polymersome-protamine vector</i>	146
<i>Polyethylenimine nanoparticles for siRNA delivery</i>	146
<i>Polycation-based nanoparticles for siRNA delivery</i>	147
<i>Quantum dots to monitor siRNA delivery</i>	147
<i>siRNA-nanoparticle conjugates for improving stability in serum</i>	148
<i>Systemic delivery of siRNAi by lipid nanoparticles</i>	148
<i>Topical delivery of siRNA-nanoparticle conjugates</i>	149
Targeted delivery of siRNAs to specific organs	149
<i>siRNA delivery to the CNS</i>	149
<i>siRNA delivery to the liver</i>	150
<i>siRNA delivery to the lungs</i>	151
Control of RNAi and siRNA levels	151
siRNA pharmacokinetics in mammalian cells	151
Mathematical modeling for determining the dosing schedule of siRNA.....	152
Assessing siRNA pharmacodynamics in animal models	152
Research on siRNA delivery funded by the NIH	153
Companies involved in delivery technologies for siRNA	153
5. RNAi in Research	156
Introduction	156
Basic RNAi research	156
<i>Antiviral role of RNAi in animal cells</i>	156
<i>Combination of siRNA with green fluorescent protein</i>	156
<i>Detection of cancer mutations</i>	157
<i>Genes and lifespan</i>	157
<i>Inducible and reversible RNAi</i>	157
<i>Loss-of-function genetic screens</i>	157
<i>Nanoparticles mimic RNAi</i>	158
<i>Profiling small RNAs</i>	158
<i>RNAi for research in neuroscience</i>	158
<i>RNAi and environmental research</i>	159
<i>Small nucleolar RNAs</i>	159
<i>Study of signaling pathways</i>	159
<i>Transgenic RNAi</i>	160
<i>Use of RNAi to study insulin action</i>	160
Applied RNAi research	160
RNAi for gene expression studies	160
Microarrays for measuring gene expression in RNAi.....	161
RNAi for functional genomic analysis	161
<i>RNAi studies on C. elegans</i>	162
<i>RNAi studies on Drosophila</i>	162
<i>RNAi in planaria</i>	163
RNAi for regenerative medicine.....	163
Testing the specificity of RNAi.....	164
Tissue-specific RNAi	164
siRNA-mediated gene silencing	164
RNAi libraries	164
<i>Enzymatic production of RNAi library</i>	165
<i>Next-generation libraries for RNAi-based genome-wide screens</i>	165
<i>pDual library using plasmid vector</i>	166
<i>pHippy plasmid vector library</i>	166
<i>siRNA libraries using pRetroSuper vector</i>	166
<i>siRNA produced by enzymatic engineering of DNA</i>	166
<i>shRNA libraries</i>	167

RNAi and alternative splicing	168
RNAi in animal development.....	168
<i>RNAi for creating transgenic animals</i>	168
<i>RNAi for creating models of neurological disorders</i>	169
Research support for RNAi in US.....	170
RNAi for toxicogenomics	170
Role of RNAi in the US biodefense research	170
The RNAi Consortium	170
Research support for RNAi in Europe.....	171
European Union for RNA Interference Technology	171
Research support of RNAi.....	172
Role of RNAi in MitoCheck project	172
RNAi Global Initiative	172
SIROCCO project.....	173
6. RNAi in drug discovery	176
Basis of RNAi for drug discovery	176
RIP-Chip for study of RNA-protein interactions.....	176
RNAi for identification of genes as therapeutic targets	177
Role of siRNAs in drug target identification	177
<i>Use of a genome-wide, siRNA library for drug discovery.....</i>	<i>178</i>
<i>Use of arrayed adenoviral siRNA libraries for drug discovery.....</i>	<i>178</i>
RNAi as a tool for assay development.....	178
Targeting human kinases with an siRNAi library	178
Challenges of drug discovery with RNAi	179
Express Track SM siRNA Drug Discovery Program.....	179
Genome-wide siRNA screens in mammalian cells	180
<i>PhenomicIDTM</i>	<i>180</i>
Natural antisense and ncRNA as drug targets	180
RNAi for target validation.....	181
<i>Delivering siRNA for target validation in vivo</i>	<i>181</i>
<i>Validation of oncology targets discovered through RNAi screens.....</i>	<i>182</i>
<i>Selection of siRNA versus shRNA for target validation</i>	<i>183</i>
Off-target effects of siRNA-mediated gene silencing	183
<i>Bioinformatic approach to off-target effects.....</i>	<i>184</i>
<i>siPools for eliminating off-target effects of siRNAs.....</i>	<i>184</i>
<i>Managing off-target effects of vector-encoded shRNAs.....</i>	<i>184</i>
Application of RNAi to the druggable genome	185
Application of siRNA during preclinical drug development.....	185
siRNAs vs small molecules as drugs.....	186
siRNAs vs antisense drugs.....	186
Chemical modifications for improving siRNA drugs	186
RNAi technology in plants for drug discovery and development.....	187
<i>Application of RNAi to poppy plant as source of new drugs</i>	<i>187</i>
7. Therapeutic applications of RNAi	188
Introduction	188
Potential of RNAi-based therapies	189
In vitro applications of siRNA	189
In vivo applications of RNAi.....	190
RNAi and cell therapy	190
Gene inactivation to study hESCs.....	191
RNAi and stem cells	191
<i>RNAi for study of ESCs</i>	<i>192</i>
<i>RNAi and iPSCs.....</i>	<i>192</i>
Cell therapy for immune disorders	192
RNAi gene therapy	192
Drug-inducible systems for control of gene expression.....	193
Potential side effects of RNAi gene therapy.....	193
Systemic delivery of siRNAs	194
In vivo RNAi therapeutic efficacy in animal models of human diseases.....	194
Role of RNAi in regenerative medicine.....	195
Virus infections.....	196
RNAi approaches to viral infections.....	196
<i>Delivery of siRNAs in viral infections</i>	<i>197</i>
RNAi applications in HIV	197
<i>A multiple shRNA approach for silencing of HIV-1.....</i>	<i>198</i>
<i>Anti-HIV shRNA for AIDS lymphoma.....</i>	<i>198</i>
<i>Aptamer-mediated delivery of anti-HIV siRNAs</i>	<i>199</i>
<i>Bispecific siRNA constructs.....</i>	<i>199</i>
<i>Role of the nef gene during HIV-1 infection and RNAi</i>	<i>199</i>

<i>siRNA-directed inhibition of HIV-1 infection</i>	200
<i>Synergistic effect of snRNA and siRNA</i>	200
<i>Targeting CXCR4 with siRNAs</i>	201
<i>Targeting CCR5 with siRNAs</i>	201
<i>Concluding remarks on RNAi approach to HIV/AIDS</i>	201
Influenza	202
<i>Inhibition of influenza virus by siRNAs</i>	202
<i>Delivery of siRNA in influenza</i>	203
<i>Challenges and future prospects of siRNAs for influenza</i>	204
Respiratory syncytial and parainfluenza viruses	204
Coronavirus/severe acute respiratory syndrome	205
Herpes simplex virus 2	205
Hepatitis B	206
Hepatitis C virus	206
Cytomegalovirus	207
Virus causing hemorrhagic fever	208
<i>Dengue fever</i>	209
<i>Antivirals in development</i>	209
<i>Ebola virus</i>	210
<i>Marburg virus</i>	210
<i>siRNA vs antisense oligonucleotides for viral infections</i>	211
siRNA against methicillin-resistant <i>S. aureus</i>	211
RNAi-based rational approach to antimalarial drug discovery	211
<i>Inhibiting the growth of malarial parasite by heme-binding DNA aptamers</i>	212
<i>siRNA-based antimalarial therapeutics</i>	212
RNAi applications in oncology	212
<i>Allele-specific inhibition</i>	213
<i>Drug delivery issues in managing cancer by RNAi approach</i>	214
<i>Inhibition of oncogenes</i>	214
<i>Modification of alternative splicing in cancer</i>	216
<i>Onconase</i>	216
<i>Overcoming drug resistance in cancer</i>	216
<i>Targeting fusion proteins in cancer</i>	217
<i>Increasing chemosensitivity by RNAi</i>	217
<i>RNAi approach to study TRAIL</i>	218
<i>RNAi-based logic circuit for identification of specific cancer cells</i>	218
<i>shRNA-based autologous cancer vaccine</i>	218
<i>siRNAs for anticancer drug discovery</i>	219
<i>siRNAs based on huntingtin trinucleotide repeats as anticancer reagents</i>	220
<i>siRNAs for inducing cancer immunity</i>	220
<i>siRNAs for inhibition of angiogenesis</i>	220
<i>siRNA targeting the R2 subunit of ribonucleotide reductase</i>	221
<i>siRNA for cancer chemoprevention</i>	221
<i>siHybrids vs siRNAs as anticancer agents</i>	221
<i>Nanobiotechnology-based delivery of siRNAs</i>	222
<i>Lipid nanoparticle-based delivery of anticancer siRNAs</i>	222
<i>Minicells for targeted delivery of nanoscale anticancer therapeutics</i>	222
<i>Nanoimmunoliposome-based system for targeted delivery of siRNA</i>	223
<i>PEG-nanoparticles for delivery of siRNA to target fusion genes</i>	223
<i>Polymer nanoparticles for targeted delivery of anticancer siRNA</i>	224
<i>RNA nanotechnology for delivery of cancer therapeutics</i>	224
<i>siRNA delivery in combination with nanochemotherapy</i>	225
<i>Targeted delivery of a nanoparticle-siRNA complex in cancer patients</i>	225
<i>Lipophilic siRNA for targeted delivery to solid tumors</i>	225
<i>RNAi-based treatment of various cancer types</i>	226
<i>RNAi-based therapy of glioblastoma multiforme</i>	226
<i>RNAi in breast cancer</i>	228
<i>RNAi for enhancing hyperthermia/chemotherapy in cervical cancer</i>	228
<i>RNAi and colorectal cancer</i>	229
<i>RNAi and Ewing's sarcoma</i>	229
<i>RNAi and leukemias</i>	230
<i>RNAi and lung cancer</i>	230
<i>RNAi and melanoma</i>	230
<i>RNAi and pancreatic cancer</i>	231
<i>RNAi and prostate cancer</i>	232
Genetic disorders	232
RNAi for skin disorders	233
<i>Experimental studies for RNAi applications in skin disorders</i>	233
<i>Clinical applications of RNAi in skin disorders</i>	233
<i>Pachyonychia congenita</i>	234
<i>Skin scarring</i>	234

Neurological disorders	234
RNAi for neurodegenerative disorders	235
<i>Alzheimer's disease</i>	236
<i>Parkinson's disease</i>	236
<i>Amyotrophic lateral sclerosis</i>	237
<i>Prion diseases</i>	238
Polyglutamine-induced neurodegeneration	238
<i>Fragile X syndrome and RNAi</i>	239
<i>RNAi-based therapy for Huntington's disease</i>	239
Combination of RNAi and gene therapy to prevent neurodegenerative disease	241
Role of RNAi in pain therapy	241
Role of RNAi in repair of spinal cord injury	242
Role of RNAi in treatment of multiple sclerosis	242
siRNA for Duchenne muscular dystrophy	243
siRNA for dystonia	243
RNAi in ophthalmology	243
Age related macular degeneration	243
<i>Current treatment of AMD</i>	244
<i>RNAi-based treatments for AMD</i>	245
Diabetic retinopathy	246
Retinitis pigmentosa	247
RNAi and metabolic disorders	247
RNAi and obesity	247
<i>Genes and regulation of body fat</i>	247
RNAi and diabetes	247
<i>Regulation of insulin secretion by a miRNA</i>	248
<i>RNAi for study of genes in animal models of diabetes</i>	248
<i>RNAi for drug discovery in diabetes</i>	248
<i>RNAi for treating liver dysfunction in diabetes</i>	249
<i>siRNAs for study of glucose transporter</i>	250
<i>siRNAs for targeting adipose inflammation in diabetes and obesity</i>	250
RNAi in hematology	250
Stem cell-based gene therapy and RNAi for sickle cell disease	251
Targeting of antithrombin in hemophilia with RNAi	252
RNAi and disorders of the immune system	252
siRNA applications in immunology	252
Use of RNAi in transplantation	253
RNAi for cardiovascular disorders	254
RNAi for hypercholesterolemia	254
siRNAs targeting PCSK9	254
siRNA targeting NADPH oxidase in cardiovascular diseases	255
Role of lncRNA in cardiovascular disorders	256
siRNA for study and treatment of ischemia-reperfusion injury	256
RNAi in respiratory disorders	257
siRNA for cystic fibrosis	257
siRNA for asthma	257
RNAi for musculoskeletal disorders	257
RNAi for rheumatoid arthritis	257
RNAi for bone disorders	259
<i>RNAi for treatment of osteoporosis</i>	259
RNAi for miscellaneous disorders	259
<i>RNAi for transthyretin amyloidosis</i>	259
Research relevant to RNAi-based therapies at academic institutes	260
Laboratory of RNA Molecular Biology, The Rockefeller University	260
RNAi Center, La Jolla Institute for Allergy & Immunology	260
Clinical trials of RNAi-based therapies	261
Improving efficacy of siRNAs for clinical trials by improved delivery	262
Role of RNAi in development of personalized medicine	262
Future of RNAi	263
Challenges for the development of RNAi-based therapeutics	263
8. Safety, regulatory and patent issues	266
Introduction	266
Limitations and drawbacks of RNAi	266
Adverse effects of RNAi	266
Effect of siRNAs on interferon response	267
Detection of interferon response	267
Prevention of the interferon response in RNAi	268
Overcoming the innate immune response to siRNAs	268
Toxicity associated with RNAi	269
Selection of siRNAs to improve specificity and efficacy	269

Regulatory issues relevant to RNAi	269
RNAi patents	270
Companies with strong patent position	270
<i>Alnylam</i>	270
<i>Benitec</i>	273
<i>Intradigm</i>	273
<i>Quark Pharmaceuticals</i>	273
<i>Sirna Therapeutics</i>	274
9. Markets for RNAi Technologies	276
Introduction	276
Current and future market potential for RNAi technologies	276
RNAi reagents	277
siRNA markets.....	277
miRNA markets	277
RNAi-based drug discovery and target validation	277
RNAi-based development of therapeutics	277
RNAi market potential according to therapeutic areas	278
Market for viral infections	278
Market for cancer.....	279
Market for age related macular degeneration.....	279
Unmet needs in RNAi	279
Strategies for marketing RNAi	280
Choosing optimal indications	280
Strategies according to the trends in healthcare in the next decade	281
Concluding remarks	282
10. Companies involved in RNAi Technologies	284
Introduction	284
Major players in RNAi	288
Profiles of companies	288
Collaborations	478
11. References	486

Tables

Table 1-1: Various types of RNA	21
Table 1-2: Classification of small RNA molecules.....	31
Table 1-3: Mechanisms of small RNAs involved in gene silencing	33
Table 1-4: Historical landmarks in the evolution of RNAi	37
Table 2-1: RNAi versus small molecules.....	43
Table 2-2: Providers of software for siRNA design	48
Table 2-3: Methods for the production of siRNAs	52
Table 2-4: Advantages and limitations of methods of shRNA-derived siRNA knockdown	60
Table 2-5: Comparison of eiRNA with siRNA	61
Table 3-1: Methods for miRNA target prediction	81
Table 3-2: miRNA expression in neurodegenerative diseases.....	93
Table 3-3: Dysregulation of miRNA expression in epithelial cancers.....	101
Table 3-4: Delivery strategies for miRNA inhibition therapies in cancer.....	108
Table 3-5: Delivery strategies for miRNA replacement to inhibit cancer growth.....	108
Table 3-6: MiRNAs and key molecules in signaling pathways in glioblastoma multiforme.....	109
Table 3-7: Companies involved in miRNA diagnostics and therapeutics.....	120
Table 3-8: Status of therapeutic development of miRNAs.....	122
Table 4-1: Methods of delivery of oligonucleotides	124
Table 4-2: Methods of delivery of siRNA	129
Table 4-3: Companies developing siRNA delivery technologies.....	153
Table 5-1: RNAi libraries.....	165
Table 6-1: Delivery of siRNAs in vivo for target validation	181
Table 6-2: Selection of siRNA versus shRNA for target validation	183
Table 7-1: RNAi-based therapeutic approaches.....	189
Table 7-2: In vivo RNAi therapeutic efficacy in animal models of human diseases	194
Table 7-3: Inhibition of viral replication by RNAi	197
Table 7-4: Cancer-associated genes that can be targeted by RNAi	215
Table 7-5: Neurological disorders that have been studied by using RNAi	235
Table 7-6: Clinical trials of RNAi-based therapeutics.....	261
Table 9-1: RNAi markets according to technologies and reagents 2017-2027	276
Table 9-2: Markets for RNAi therapy for selected diseases: years 2017-2027	278
Table 10-1: RNAi reagent, technology and service companies	284

Table 10-2: Pharmaceutical companies using RNAi for drug discovery and development	285
Table 10-3: Biotechnology companies using RNAi for drug discovery and development.....	286
Table 10-4: Companies developing RNAi-based therapeutic products	287
Table 10-5: Major players in RNAi.....	288
Table 10-6: Proprietary reagents of ImuThes	363
Table 10-7: Product pipeline of Silence Therapeutics	447
Table 10-8: Collaborations in RNAi technologies	478

Figures

Figure 1-1: Relationship of DNA, RNA and protein in the cell	23
Figure 1-2: tsRNAs in a model of hepatocellular carcinoma	30
Figure 1-3: Schematic of suppression of gene expression by RNAi	32
Figure 1-4: Relation of RNAi to epigenetic mechanisms	36
Figure 2-1: Overview of ShortCut RNAi Kit.....	44
Figure 2-2: Gene silencing by RNAi induced with ddRNAi	58
Figure 2-3: saRNA for targeted gene activation	63
Figure 3-1: A schematic miRNA pathway with points of action of miRNA tools	64
Figure 3-2: Molecular mechanisms of miRNA generation.....	65
Figure 3-3: miRNA alternations in neurodegenerative diseases	92
Figure 4-1: RNA aptamer-mediated targeted RNAi delivery in cancer therapy.....	131
Figure 7-1: Targeting disease by RNAi.....	188
Figure 7-2: Mechanism of action of inclisiran	255
Figure 7-3: Role of RNAi in personalized medicine.....	262
Figure 8-1: Problems with use of synthetic siRNAs and measures to prevent them.....	267
Figure 9-1: Unmet needs in RNAi technologies	280